Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paolo Marchetti

Showing results (311-320 of 415) with videos related to

Pageof 42
Sort By:
Journal of Translational Medicine|June 3, 2014
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Cancers|January 22, 2021
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future PerspectivesMichela Roberto, Antonio Astone, Andrea Botticelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2019
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Alice Lunghi, Enrico Cortesi, et al.
Journal of Medicinal Chemistry|November 10, 2011
Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90Riccardo Baruchello, Daniele Simoni, Giuseppina Grisolia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Frontiers in Immunology|November 21, 2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapyAndrea Botticelli, Giulia Pomati, Alessio Cirillo, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Pageof 42

Showing results (311-320 of 415) with videos related to

Sort By:
Pageof 42
Journal of Translational Medicine|June 3, 2014
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohortPaolo A Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
Cancer Treatment Reviews|August 28, 2023
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spreadCarmen Criscitiello, Chiara Corti, Michelino De Laurentiis, et al.
Targeted Oncology|September 24, 2022
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 StudyMichelino De Laurentiis, Roberta Caputo, Manuelita Mazza, et al.
Cancers|January 22, 2021
CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future PerspectivesMichela Roberto, Antonio Astone, Andrea Botticelli, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2019
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access programEditta Baldini, Alice Lunghi, Enrico Cortesi, et al.
Journal of Medicinal Chemistry|November 10, 2011
Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90Riccardo Baruchello, Daniele Simoni, Giuseppina Grisolia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2019
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with NivolumabUgo De Giorgi, Giuseppe Procopio, Diana Giannarelli, et al.
Frontiers in Immunology|November 21, 2022
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapyAndrea Botticelli, Giulia Pomati, Alessio Cirillo, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
Journal of Experimental & Clinical Cancer Research : CR|April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeVanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
Pageof 42